%0 Journal Article
%T Botulinum Toxin Type A Satisfaction in Different Neurological Disorders
%A Jasem Yousef Al-Hashel
%A Doaa Youssry Soliman
%A Ismail Ibrahim Ismail
%A Samar Farouk Ahmed
%J Neuroscience & Medicine
%P 1-16
%@ 2158-2947
%D 2022
%I Scientific Research Publishing
%R 10.4236/nm.2022.131001
%X <strong>Background:</strong> The botulinum toxin type A (BoNT-A) is used in a wide range of neurological diseases. We aimed to study the overall patients/caregivers¡¯ satisfaction with BoNT-A treatment in different neurological conditions. <strong>Methods:</strong> Prospective study included patients who had received at least two BoNT-A treatment sessions. They were asked to rate overall treatment satisfaction at the peak of treatment effect on a 1 to 10 scale (1 = <em>not at all satisfied</em>; 10 = <em>fully satisfied</em>). Subjects with a rating of 1to3 were classified as not at all satisfied, those with a rating of 4 to7 as somewhat satisfied, and those with a rating of 8 to10 as very satisfied. Treatment satisfaction questionnaire for medicine (TSQM) was assessed at the end of observational period. Quality of life QOL was assessed before BoNT-A treatment and at the last visit. <strong>Results:</strong> The study was conducted from first April 2014 to August 2021. 548 patients were identified with mean age 43.66 ¡À 14.50. Most of participants 389 (71%) were female. At the end of observational period, the mean satisfaction was 7.28 ¡À 1.78. There was a highly significant difference (<em>P</em> &lt; 0.0001) for treatment satisfaction among different neurological disorders. Total TSQM with BoNT-A was the highest for axillary hyperhidrosis (HH) (90.45 ¡À 0.62), followed by chronic migraine (72.13 ¡À 1.59) and the least TSQM was reported in writer¡¯s cramp (40.44 ¡À 1.57). Overall satisfaction with BoNT-A at the peak of treatment effect among patients with axillary HH (100%), palmar HH (94.4%), neuropathic pain syndromes (85.7%), planter HH (90%), trigeminal neuralgia (80%). While patients with cervical dystonia (86.7%) and musculoskeletal pain (80%) patients were somewhat satisfied. Not at all satisfied rates were recorded among writer¡¯s cramp patients (40%). Total TSQM with BoNT-A was highest for axillary HH 90.45 ¡À 0.62 and least satisfaction was reported in writer¡¯s cramp 40.44 ¡À 1.57. QOL significantly improved at the end of observational period (71.93 versus 104.52; <em>P</em> &lt; 0.0001).We reported a positive significant correlation between BoNT-A treatment satisfaction and treatment adherence (r = 0.242, <em>P</em> = 0.001). <strong>Conclusion:</strong> Satisfaction with BoNT-A therapy for different neurological disorders is overall good. The highest patient satisfaction was observed with primary focal HH, and the least satisfaction was observed in writer¡¯s cramp. BoNT-A therapy improved QOL.
%K Botulinum Toxin Type A
%K Satisfaction
%K Headache
%K Dystonia
%K Movement Disorders
%K Hyperhidrosis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=115387